Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,381
Total Claims
$1.2M
Drug Cost
469
Beneficiaries
$2,482
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+511%
Opioid rate vs peers
13.7% vs 2.2% avg
+76%
Cost per patient vs peers
$2,482 vs $1,411 avg
+2%
Brand preference vs peers
10.8% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid prescribing rate is 511% above the average for Internal Medicine providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
13.7%
Opioid Rate
1,282
Opioid Claims
$32K
Opioid Cost
0.9%
Long-Acting Rate
Brand vs Generic
Brand: 1,002 claims · $981K
Generic: 8,275 claims · $177K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 73 | $99K |
| Empagliflozin | 35 | $62K |
| Insulin Glargine,hum.Rec.Anlog | 64 | $61K |
| Apixaban | 70 | $55K |
| Insulin Detemir | 46 | $51K |
| Abacavir/Dolutegravir/Lamivudi | 13 | $50K |
| Dolutegravir Sodium | 13 | $30K |
| Semaglutide | 18 | $30K |
| Hydrocodone/Acetaminophen | 1,049 | $28K |
| Insulin Aspart | 27 | $26K |
| Insulin Lispro Protamin/Lispro | 19 | $22K |
| Rivaroxaban | 21 | $19K |
| Mirabegron | 24 | $18K |
| Insulin Detemir | 20 | $17K |
| Fluticasone/Umeclidin/Vilanter | 16 | $16K |
Prescribing Profile
Patient Profile
71
Avg Age
55%
Female
2.38
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data